PRCT Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -1.86%, SMA50 -9.41%, SMA200 -32.16%). The stock’s 14-day RSI is 43.42 (neutral), while the ATR of 1.52 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -60.68% below its high and over 6.14% above its low. Average 10-day trading volume of 1.49 million shares is slightly above the 3-month average of 1.25 million, indicating heightened recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

PROCEPT BioRobotics Corporation has 55.64 million shares outstanding. The public float is 53.56 million shares, elevated short interest at 17.19% of float. This equals 8.07 million shares. The short ratio is 5.15 days. Institutional investors hold 102.82% of the float. Insiders own 4.63%. CPMG Inc holds 11.22 million shares, MOLL FREDERIC H has 863.16 thousand shares and VIKING GLOBAL INVESTORS LP has 400.00 thousand shares.

PROCEPT BioRobotics Corporation generated EPS of -$1.54 over the past year. Five-year average earnings growth is -12.56%. Wall Street analysts project EPS growth of 24.96% annually over the next five years. The latest quarter delivered EPS of -$0.38. The next quarter is forecast at -$0.44. Next year's EPS is expected at $13.49. Analyst sentiment is bullish. Analyst rating data shows there are 9 Strong Buy ratings, 5 Buy ratings, 1 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $95.00 to $38.00. The high target offers 241.24% upside. The low target suggests 36.49% downside. The mean target is $58.69. This offers 110.81% upside. PROCEPT BioRobotics Corporation earnings surprise history is frequent misses against expectations. The quarter that ended November 04, 2025, missed forecasts by -7.32%. The prior quarter beat by -14.63%. Over the last six quarters, Apple has recorded several small beats. These include -3.85% in August 01, 2024.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) closed at $23.63 USD, losing -$4.21 (-15.12%) from the previous close of $27.84. The stock is currently mid-range between its 52-week high and low $19.35 and $70.80. With a market capitalization of about $1.32 billion, PROCEPT BioRobotics Corporation is classified as a small-cap and shows market-like volatility (beta ~0.98). Key stats such as the average daily volume over the past year has been around 1.27 million shares, trading with heavier-than-usual volume. Headquartered in San Jose, CA, PROCEPT BioRobotics Corporation operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Larry L. Wood, the company employs approximately 756 people and listed since September 15, 2021. PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology.

PROCEPT BioRobotics Corporation trades at a P/E ratio of -13.84, slightly below the S&P 500 average, with a price-to-sales ratio of 4.33 and a price-to-book ratio of 3.48 trading at moderately above to book value. The P/FCF stands at -16.74, also below market averages.

Our AI price prediction model suggests that PROCEPT BioRobotics Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.93%, with price expected at $26.19 by March 11, 2026, within a range of $25.43 to $26.95 3-Month Outlook: Projected fall of -17.31%, reaching $23.02 by May 26, 2026, with a range of $18.04 to $25.04. 1-Year Outlook: Projected gain of 14.73%, with price at $31.94 by February 25, 2027, within a range of $25.80 to $38.65.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shares are flat -3.66% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows PROCEPT BioRobotics Corporation trading at a premium to the broader market with a P/E of -13.84. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $62.64, suggesting 125.0% upside. Our AI forecast model points to short-term weakness (-5.93% over two weeks), a medium-term fall (-17.31% over three months), and a longer-term gain (14.73% over one year), with expected trading ranges indicating moderate volatility.